SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Knibbe Catherijne A. J.)
 

Sökning: WFRF:(Knibbe Catherijne A. J.) > (2014) > A Neonatal Amikacin...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003052naa a2200361 4500
001oai:DiVA.org:uu-212990
003SwePub
008131217s2014 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2129902 URI
0247 a https://doi.org/10.1007/s11095-013-1197-y2 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a De Cock, Roosmarijn F W4 aut
2451 0a A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates
264 c 2013-09-25
264 1b Springer Science and Business Media LLC,c 2014
338 a print2 rdacarrier
520 a PURPOSERecently, a covariate model characterizing developmental changes in clearance of amikacin in neonates has been developed using birth bodyweight and postnatal age. The aim of this study was to evaluate whether this covariate model can be used to predict maturation in clearance of other renally excreted drugs.METHODSFive different neonatal datasets were available on netilmicin, vancomycin, tobramycin and gentamicin. The extensively validated covariate model for amikacin clearance was used to predict clearance of these drugs. In addition, independent reference models were developed based on a systematic covariate analysis.RESULTSThe descriptive and predictive properties of the models developed using the amikacin covariate model were good, and fairly similar to the independent reference models (goodness-of-fit plots, NPDE). Moreover, similar clearance values were obtained for both approaches. Finally, the same covariates as in the covariate model of amikacin, i.e. birth bodyweight and postnatal age, were identified on clearance in the independent reference models.CONCLUSIONSThis study shows that pediatric covariate models may contain physiological information since information derived from one drug can be used to describe other drugs. This semi-physiological approach may be used to optimize sparse data analysis and to derive individualized dosing algorithms for drugs in children.
7001 a Allegaert, Karel4 aut
7001 a Sherwin, Catherine M T4 aut
7001 a Nielsen, Elisabet Iu Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Farmakometri4 aut0 (Swepub:uu)elnie838
7001 a de Hoog, Matthijs4 aut
7001 a van den Anker, Johannes N4 aut
7001 a Danhof, Meindert4 aut
7001 a Knibbe, Catherijne A J4 aut
7102 a Uppsala universitetb Institutionen för farmaceutisk biovetenskap4 org
7730 t Pharmaceutical researchd : Springer Science and Business Media LLCg 31:3, s. 754-767q 31:3<754-767x 0724-8741x 1573-904X
8564 u https://lirias.kuleuven.be/bitstream/123456789/624215/2/Pharm%20Res%202014%20covariate%20model%20AG%20neonates.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-212990
8564 8u https://doi.org/10.1007/s11095-013-1197-y

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy